Marginal Zone Lymphoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Suspended
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
U
Recruiting
  • Non-Hodgkin Lymphoma
  • +7 more
  • Mosunetuzumab
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-28
Mar 28, 2022
B
Not yet recruiting
  • Follicular Lymphoma
  • +2 more
  • New Haven, Connecticut
  • +2 more
2022-03-14
Mar 14, 2022
C
Recruiting
  • Marginal Zone Lymphoma
  • Wien, Austria
  • +19 more
2022-03-14
Mar 14, 2022
Q
Recruiting
  • Follicular Lymphoma
  • +7 more
  • Louisville, Kentucky
  • +4 more
2022-03-11
Mar 11, 2022
I
Recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • Duarte, California
  • +12 more
2022-03-24
Mar 24, 2022
U
Not yet recruiting
  • Marginal Zone Lymphoma
  • Loncastuximab tesirine 150 µg/Kg
  • Loncastuximab tesirine 75µg/Kg
  • (no location specified)
2022-03-15
Mar 15, 2022
C
Recruiting
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Duarte, California
  • +2 more
2022-03-09
Mar 9, 2022
C
Active, not recruiting
  • Adult Immunoblastic Lymphoma
  • +12 more
  • Cytology Specimen Collection Procedure
  • Birmingham, Alabama
  • +129 more
2022-03-23
Mar 23, 2022
U
Active, not recruiting
  • Non Hodgkin Lymphoma
  • +8 more
  • Miami, Florida
  • +2 more
2022-03-08
Mar 8, 2022
T
Active, not recruiting
  • Diffuse Large B-Cell Lymphoma
  • +4 more
  • Ublituximab
  • +2 more
  • Birmingham, Alabama
  • +167 more
2022-03-22
Mar 22, 2022
B
Recruiting
  • B-cell Malignancy
  • +4 more
  • Louisville, Kentucky
  • +4 more
2022-03-22
Mar 22, 2022
T
Recruiting
  • CLL
  • +9 more
  • TG-1801
  • Ublituximab
  • Fayetteville, Arkansas
  • +4 more
2022-03-22
Mar 22, 2022
J
Not yet recruiting
  • B-Cell Lymphoma
  • +8 more
  • Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
  • Pittsburgh, Pennsylvania
    AHN Cancer Institute - West Penn Hospital
2022-03-08
Mar 8, 2022
C
Recruiting
  • Marginal Zone Lymphoma
  • Bochum, Germany
  • +15 more
2022-03-14
Mar 14, 2022
A
Active, not recruiting
  • Lymphoma, B-Cell
  • +8 more
  • Scottsdale, Arizona
  • +9 more
2022-03-10
Mar 10, 2022
M
Recruiting
  • Follicular Lymphoma (FL)
  • +2 more
  • Tucson, Arizona
  • +97 more
2022-03-10
Mar 10, 2022
M
Recruiting
  • Marginal Zone Lymphoma
  • Los Angeles, California
  • +12 more
2022-03-09
Mar 9, 2022
B
Recruiting
  • Mantle Cell Lymphoma
  • +9 more
  • L-Bcl-2 antisense oligonucleotide
  • Augusta, Georgia
  • +2 more
2022-03-08
Mar 8, 2022
M
Recruiting
  • Follicular Lymphoma (FL)
  • +2 more
  • Zandelisib (ME-401)
  • Tucson, Arizona
  • +115 more
2022-03-08
Mar 8, 2022
U
Recruiting
  • Marginal Zone Lymphoma
  • Graz, Austria
  • +10 more
2022-03-07
Mar 7, 2022
J
Active, not recruiting
  • Follicular Lymphoma
  • +3 more
  • Vitamin D
  • +2 more
  • Miami, Florida
  • +6 more
2022-03-06
Mar 6, 2022